The facilitating cell platform technology (FCRx) is a novel proprietary allogenic cell-based therapy in development in organ transplant to deliver stable graft function without the toxicity of immunosuppressive agents while avoiding graft-versus-host disease (GvHD). FCRx therapies are manufactured from donor peripheral blood cells eliminating GvHD-producing cells and enriching for appropriate levels of hematopoietic stem/progenitor cells and facilitating cells. In a Phase 2 clinical study, FCRx has been shown to be useful for the prophylaxis of organ rejection by establishing donor-specific allogeneic tolerance, eliminating the need for chronic immunosuppressive therapy in adult patients receiving living donor kidney transplants following reduced intensity conditioning. There is now a substantial body of clinical evidence to indicate that FCRx represents a transformative advancement over existing forms of kidney graft maintenance, providing a significant reduction in morbidity and mortality outcomes. Unlike standard hematopoietic stem cell transplants, which require a high degree of human leukocyte antigen (HLA) matching, FCRx allows transplants to be performed in up to unmatched, unrelated patients, thereby significantly expanding the donor pool. FCRx holds the potential to be utilized in a wide variety of organ transplants and to treat other conditions including red blood cell disorders (e.g. sickle cell disease, thalassemia), select autoimmune disorders, and inherited metabolic disorders.